Wednesday, March 05, 2025 | 01:52 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Dr Reddy's signs definitive agreement to sell its API business in Hyderabad

The business will be sold to Therapiva Pvt Ltd, a joint venture between Omnicare Drugs India and Laxai Life Sciences Private Ltd

Dr Reddy's
Premium

BS Web Team New Delhi
Dr Reddy's Laboratories on Monday said it had signed a definitive agreement to sell its active pharmaceutical ingredient (API) manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Pvt Ltd, an emerging generics pharmaceutical company. The divestiture by way of slump sale includes all related fixed assets, current assets, current liabilities, and its employees.

"The divestiture of our API manufacturing business unit is a step towards streamlining our manufacturing operations and optimizing our cost structures," Sanjay Sharma, the company's executive vice-president & head of Global Manufacturing Operations, said. "We are confident that we have found in Therapiva, a buyer-partner who fully

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in